ImmunityBio Q2 Revenue Hits $50.7M, Up 92% YoY; Cash at $357M
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio delivered record Q2 product revenue of $50.7 million, a 92% jump from last year and 15% above Q1. First-half revenue reached $94.8 million, already approaching the full-year 2025 total of $113 million. The company holds $357.4 million in cash, providing a solid runway for its expanding clinical pipeline. This marks the eighth straight quarter of sequential growth for ANKTIVA, now approved in five jurisdictions covering 34 countries. The strong top-line momentum and cash position stand out against a backdrop of ongoing legal challenges and a wider net loss driven by non-cash fair value adjustments. The revenue trajectory suggests ANKTIVA is gaining real commercial traction, which could shift the narrative from a cash-burning biotech to a sustainable commercial story.
Updates
· SEC 8-K — Q2 net loss was $230.4 million, or $0.22 per share, compared with $92.6 million a year earlier. Adjusted net loss was $81.0 million, down from $89.9 million.
At the time of this announcement, IBRX was trading at $7.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.